Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma.

In recent years, targeted therapies such as pazopanib and olaratumab achieved a highly significant improvement in survival for patients with metastatic uLMS [ 41 , 42 ].

also in 132,142 other papers

Modern multimodal therapy or combining chemotherapy with aggressive surgery in selected patients may be significant in prolonging survival of women with this fatal disease [ 13 ].

also in 13,097 other papers